5G Mobile Networks DO NOT spread COVID-19. Viruses cannot travel on radio/waves mobile networks. COVID-19 is affecting many countries that do not have 5G mobile networks.
COVID-19 is spread via respiratory droplets when an infected person coughs, sneezes and speaks. Coronavirus can also be transmitted by touching a contaminated surface and then their eyes, mouth or nose.
Cold weather and snow CANNOT kill the coronavirus. By the same token, there is no reason to believe that cold weather can kill the new coronavirus or other diseases. The normal human body temperature remains around 37°C, regardless of the external temperature. To reiterate, the most effective way to protect yourself from the virus is by frequently washing your hands and practising social distancing/self-isolation/shielding.
Drinking alcohol does not protect you against COVID-19 and can be dangerous. Excessive or frequent alcohol consumption can put your health at further risk.
Being able to hold your breath for 10 seconds or more without coughing or feeling discomfort DOES NOT mean you are free from the coronavirus disease. The most common symptoms of COVID-19 are dry cough, tiredness and fever. Some people may develop more severe forms of the disease, such as pneumonia.
Ultraviolet disinfection lamps CANNOT kill the coronavirus. UV lamps should not be used to sterilise hands or other areas of skin as UV radiation can cause skin irritation.
Taking a hot bath does not prevent the coronavirus disease. Although a great way to unwind, taking a bath does not prevent COVID-19. Your normal body temperature is maintained, regardless of the temperature of your bath or shower.
Exposing yourself to the sun or temperatures above 25 degrees DOES NOT prevent coronavirus. You can catch COVID-19 regardless of the temperatures. Countries with hot weather have reported cases of COVID-19. The best way to protect yourself is to make sure you wash your hands frequently and thoroughly and avoid touching your eyes, mouth and nose.
Please take a moment to read this important announcement from Mallinckrodt Pharmaceuticals in regard to the clinical trial of Adrabetadex for NPC-1. We recognise that this may be a surprising and disappointing development for our community as a whole. Please be assured that we are advocating for further, clearer information and will follow up with our response and next steps shortly.
Sandra Cowie, President, INPDA
Joslyn Crowe, Executive Director, NNPDF
Toni Mathieson, Chief Executive, NPUK